In 2011 the cancer and NCD community made history with the adoption of the UN Political Declaration on the Prevention and Control of NCDs, which recognised NCDs as a global health and development priority and committed governments to take urgent action to address this growing crisis. Building on the momentum created by the Political Declaration and subsequent resolutions by the World Health Assembly, a new global framework for NCDs has emerged:
The GMF and GAP include cancer-specific targets, actions and indicators in the areas of cancer planning and surveillance; vaccination for HPV and HBV against cervical and liver cancers; early detection and screening for breast, cervical, oral and colorectal cancers linked to timely treatment; access to essential medicines and technologies and; palliative care policies.
Following the decision of the 140th session of the WHO Executive Board in Jan. 2017, Member States endorsed an updated Appendix 3 to the WHO GAP. This update took into account the emergence of new evidence of cost-effectiveness and the issuance of new WHO recommendations since the GAP's adoption in 2013.
Specific interventions with WHO-CHOICE analysis for cancer control include new additions on early detection and treatment of stage I and II cancers for cervical, breast, colorectal and oral cancers, as well as a basic palliative care package for cancer.
For more information on the update to Appendix 3, tune in to Dr Julie Torode, Deputy CEO and Advocacy and Networks Director on the available recorded webinar.